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Abstract Time is an important aspect of health economic
evaluation, as the timing and duration of clinical events,
healthcare interventions and their consequences all affect
estimated costs and effects. These issues should be reflec-
ted in the design of health economic models. This article
considers three important aspects of time in modelling: (1)
which cohorts to simulate and how far into the future to
extend the analysis; (2) the simulation of time, including
the difference between discrete-time and continuous-time
models, cycle lengths, and converting rates and probabili-
ties; and (3) discounting future costs and effects to their
present values. We provide a methodological overview of
these issues and make recommendations to help inform
both the conduct of cost-effectiveness analyses and the
interpretation of their results. For choosing which cohorts
to simulate and how many, we suggest analysts carefully
assess potential reasons for variation in cost effectiveness
between cohorts and the feasibility of subgroup-specific
recommendations. For the simulation of time, we recom-
mend using short cycles or continuous-time models to
avoid biases and the need for half-cycle corrections, and
provide advice on the correct conversion of transition
probabilities in state transition models. Finally, for dis-
counting, analysts should not only follow current guidance
and report how discounting was conducted, especially in
the case of differential discounting, but also seek to
develop an understanding of its rationale. Our overall
recommendations are that analysts explicitly state and
justify their modelling choices regarding time and consider
how alternative choices may impact on results.
Key Points for Decision Makers
Time is an important aspect of the accurate
modelling of cost effectiveness in ways that are not
always obvious or made explicit in cost-
effectiveness analyses.
The choice of cohorts and time horizons in the model
should depend on which cohorts will be affected by
the policy decision and how long that policy will
apply.
Cost-effectiveness estimates can be very sensitive to
discounting; therefore, not only should discounting
be applied correctly but alternatives to the standard
discounting model should not be adopted without
careful consideration.
1 Introduction
Time is a continuous measure used to order sequences of
events and to quantify the periods between them. It is an
important aspect of health economic evaluation, as the
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timing and duration of clinical events, healthcare inter-
ventions and their consequences all have implications for
estimated costs and effects [1, 2]. In addition, the policy
questions informed by health economic analyses can vary
in their scope in time. Some policy choices only have
short-term implications, whereas the outcomes of others
may be felt decades later, either because the effects are not
realised immediately or because they affect both current
and future cohorts. Therefore, health economic models
need to simulate time appropriately if they are to reliably
inform resource allocation. Despite their central impor-
tance the choices regarding time in modelling are often not
explicitly stated. Consequently, it is often unclear how time
influences both the technical adequacy of models and their
correspondence to the policy choices they seek to inform.
This article reviews three principal methodological
issues in the modelling of time in cost-effectiveness anal-
ysis (CEA). First, we address the structure of models with
respect to time, including which cohorts to simulate and the
implications this has for how far into the future to extend
the analysis. Second, we address time with respect to the
running of simulation models, including the difference
between discrete-time and continuous-time models, how to
choose the cycle length and how to accurately convert rates
to probabilities. Finally, we address the theory and practice
of discounting future costs and effects to their present
values to account for time preference and intertemporal
opportunity costs.
The purpose of this article is to provide both a guide to
the concept of time for those conducting health economic
evaluations and an aid to those interpreting findings from
the literature. It considers time primarily in the context of
simulation modelling for CEA. However, the issues dis-
cussed are also relevant for related forms of evaluation,
such as budget impact analysis and comparative effec-
tiveness analysis. Although this article cannot be exhaus-
tive in scope or detail, it seeks to provide an accessible
overview and an introduction to the relevant literature. It is
hoped that this article will encourage analysts to consider
time carefully and write more explicitly about how time
relates to the modelling of decision problems.
2 Cohort Selection and Time Horizons
An important modelling choice is how long to simulate the
implementation of an intervention and its consequent
effects. This choice largely depends on whether the inter-
vention’s effects are transitory or permanent, how many
cohorts are simulated and whether the intervention has any
shared effects. A number of factors that influence cost
effectiveness vary with both age and calendar time,
therefore these questions of how long to simulate an
intervention’s implementation and over how many cohorts
are important for model estimates. For example, rates of
disease progression vary with age and health technologies
and epidemiological characteristics change over time.
Consequently, an intervention’s cost effectiveness should
not be considered a fixed property, but specific to the
population and time period in question. The following
sections further describe cohort selection before consider-
ing the implications for model time horizons.
2.1 Cohort Selection
A cohort is a number of intervention recipients grouped
together for analytical purposes. Many CEAs use single-
cohort models [3], which simulate one cohort of patients
over time. By contrast, multi-cohort models simulate
multiple recipient cohorts. Although cohorts can be dif-
ferentiated by other factors, such as sex, race and year of
diagnosis, this article focuses on cohorts that are differ-
entiated by their birth year. Closed models are defined as
models that simulate only those cohorts present in the
initial period, whereas open models allow new cohorts to
enter over time [4, 5]. Some refer to such open models as
population models [6, 7].
The policy choices facing decision makers are usually
not for a single cohort of intervention recipients. Never-
theless, single-cohort models have the benefit of conceptual
simplicity and can be adequate to answer the resource
allocation decision in certain circumstances. Indeed, the
widespread use of single-cohort models may reflect an
often implicit assumption that the cost effectiveness
demonstrated in a given cohort is representative for other
cohorts, both now and in the future. Such an assumption is
reasonable if there are no relevant differences between
cohorts, there are no (relevant) shared effects between
cohorts and if large real price changes or technological
innovations are not anticipated in the near future.
In some cases there will be important differences in cost
effectiveness between cohorts; therefore, it can be helpful
to differentiate between types of cohorts. We can define the
new recipient cohorts in any given year as the incident
cohorts and the cohorts already eligible for the intervention
as the prevalent cohorts. For example, the introduction of
an age-based prevention programme such as screening will
affect three principal categories of cohorts: (1) the current
incident cohort with current age equal to the screening start
age; (2) the prevalent cohorts already aged within the
screening age range; and (3) future incident cohorts that
will age into the screening age range as time progresses.
These three categories are represented in Fig. 1 in a
hypothetical intervention that takes 3 years per patient to
complete as cohorts 3, 1 and 2, and 4–7, respectively. The
distinction between incident and prevalent cohorts only
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applies to interventions that take a long time to complete
per cohort. This example can be contrasted with infant
bloodspot screening. Since infant bloodspot screening only
occurs once and the duration of intervention for a given
cohort is short, such an intervention will only have one
eligible cohort in any given year.
Differences between the current incident cohort and
future incident cohorts are one obvious reason for using a
multi-cohort model [8]. For example, in the context of
screening for the prevention of cervical cancer, the vacci-
nation of teenage girls against human papillomavirus
(HPV) means that the expected incidence of disease in
future cohorts is lower, with the result that screening is
anticipated to be less cost effective than in the current
incident cohort of unvaccinated women [9]. Multi-cohort
models that include future incident cohorts can account for
such differences.
A second, but less obvious, reason for using multi-co-
hort models is the differences between the current incident
and prevalent cohorts [10]. For example, in an aged-based
screening programme the prevalent cohorts start screening
part-way through the eligible screening age range, and thus
only receive what remains of the screening schedule. The
cost effectiveness of this remaining portion of the inter-
vention will likely differ from the complete screening
schedule. Multi-cohort models can be used to account for
such differences.
A third and important reason for using multi-cohort
models is to simulate shared effects between cohorts, such
as herd immunity due to vaccination against an infectious
disease. These simulations often involve multiple cohorts
and employ transmission dynamic models, in which the
risk of infection varies with the proportion of the popula-
tion infectious at a given time [11]. Such shared effects
models typically simulate all individuals in whom trans-
mission may be affected rather than only those who receive
the intervention in question. For example, in the case of
childhood influenza vaccination the entire population will
often be modelled, as transmission can take place across all
age groups [12].
When using multi-cohort models, analysts should con-
sider whether to report estimates aggregated over all
cohorts, or to report disaggregated results for specific
subgroups [9, 13]. This choice largely depends on whether
subgroup-specific policy choices are feasible. Cohort-
specific estimates are less meaningful where there are
shared effects between cohorts, such as in infectious dis-
eases, as it is not possible to isolate cohort-specific effects.
If estimates for multiple cohorts are aggregated together,
the number of cohorts modelled and the consequences this
has for incremental cost-effectiveness ratios (ICERs) and
the correspondence to policy questions should be carefully
considered [9].
We recommend that analysts explicitly define the sim-
ulated cohorts and describe how they relate to the policy
choices faced by decision makers with respect to the
patient population and time period in question. If none of
the reasons for including multiple cohorts apply, we rec-
ommend using single-cohort models in the interests of
parsimony. For multi-cohort models we recommend that
the choice of reporting aggregate or disaggregated esti-
mates is justified.
2.2 Intervention Duration, Implementation Period
and Analytic Horizon
The number of cohorts modelled and the simulation of
shared effects have implications for how long an inter-
vention should be simulated and how long to assess its
effects. There is a lack of consensus terminology regarding
time horizons in CEA modelling. To address this we define
and then provide advice around three important choices.
The first is the intervention duration, which we define as
the length of time over which the intervention is applied
per person or cohort. This may be short in the case of infant
bloodspot screening or be lifelong where a medication is
taken daily until death. The intervention duration is
inherent to the intervention itself and generally we rec-
ommend modelling until the completion of the intervention
duration for all recipient cohorts. Curtailing the interven-
tion duration, therefore, is to model a shorter course of an
intervention than would be expected in reality, and, hence,
may be unrepresentative of actual costs and effects.
Fig. 1 A multi-cohort model illustrating a 3-year intervention
duration, a 5-year implementation period and a lifetime analytic time
horizon. Each bar represents the lifespan of a cohort with a life
expectancy of 80 years. The oldest cohort is born in 1943 and dies in
2023. The intervention starts at age 70 years and implementation
begins in 2015; consequently, the two oldest cohorts start the
intervention after age 70 years. If the implementation period were
sufficiently long, all cohorts would complete the intervention.
However, imposing a 5-year implementation period will censor some
implementation for the youngest two cohorts. If effects are assessed
until the death of the youngest cohorts then the analytic horizon is the
year 2029
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Next, we define the implementation period as the period
over which the intervention is applied over all simulated
cohorts. This is identical to the intervention duration in a
single-cohort model. In a multi-cohort model it is typically
the time between the start of the intervention for the first
cohort and the end of the intervention for the last cohort.
However, in some cases analysts constrain the implemen-
tation period to some point in time before the conclusion of
the intervention for all cohorts [14, 15]. For example, in
Fig. 1 a five year implementation horizon would curtail
implementation for some cohorts at year 2020. Whereas
some cohorts (cohorts 3–5) complete the full intervention,
other cohorts (cohorts 6 and 7) are constrained from
completing the full course. To avoid curtailing the inter-
vention duration we recommend specifying a sufficiently
long implementation period.
Finally, we define the analytic horizon as the period
over which costs and effects are assessed. The time horizon
should generally be long enough to capture all meaningful
differences in costs and effects between alternatives con-
sidered [16], which in many cases will be the lifetime of
the cohorts modelled. Analyses with analytic horizons
shorter than the cohorts’ lifetimes potentially omit relevant
outcomes and therefore may provide incorrect results [13].
Some modellers adopt a cross-sectional approach that
imposes a common implementation and analytic horizon
over multiple cohorts; in some cases, this horizon is shorter
than the cohorts’ lifetimes [17]. This cross-sectional
interpretation contrasts with the more conventional longi-
tudinal approach that appraises outcomes over the lifetime
of the modelled individuals [18]. The cross-sectional
approach has been recognised as less useful for appraising
cost effectiveness and more relevant for assessing popu-
lation health and budget impact [19, 20]. Such cross-sec-
tional models are sometimes described as population
models, although this is not necessarily the same inter-
pretation that population models are open models.
There are some common issues that apply to these three
aspects of models. Models are typically used only to sim-
ulate a finite period of implementation and consequent
effects [21], whereas the actual period of implementation
and effects is often open-ended. For example, the inter-
vention itself may be implemented permanently (e.g.
having a continuous implementation period) or the result-
ing effects may be unending (e.g. with the eradication of an
infectious disease). While decision models can be extended
to include additional incident cohorts and the scope of
appraisal may extend long into the future, this inevitably
comes at the costs of increasingly uncertain estimates.
Therefore, it is often appropriate to limit the analysis to the
most immediate cohorts for which policy decisions are
required, provided that the intervention has no shared
effects.
In the case of interventions with shared effects, the choice
of the number of cohorts to simulate, the implementation
period and the analytic horizon all require particular con-
sideration. Infectious disease models often apply a long
implementation period simulating multiple future cohorts
[22]. This is to capture the changes in disease incidence and
transmission dynamics over time following the introduction
of the intervention. Since some of the effects of the inter-
vention may occur in cohorts other than the intervention’s
direct recipients, there is often no natural lifetime horizon to
apply [23]; however, the simulation still needs to cease
somewhere. Accordingly, the cross-sectional approach
described above is sometimes used. While this inevitably
censors some implementation and effects, the omission of
future outcomes can become negligible when the model is
run far into the future due to discounting (simulating
100 years of vaccination is not uncommon [22]). Current
practice formost of suchmodels is to halt the simulation once
infection rates stabilise [22]; alternatively, the time horizon
may be selected using the near-stabilisation of ICERs as a
criterion. Although the uncertainty of estimates for the dis-
tant future may be high, a long timeframe seems to be the
only way to obtain unbiased cost-effectiveness estimates for
many interventions with shared effects.
Analyses typically assume that the intervention and
related technologies remain stable over the period mod-
elled. This is a pragmatic assumption as the emergence of
new technologies typically cannot be anticipated. There-
fore, it is advisable that all simulated cohorts complete
their intervention duration, even though in actuality the
intervention may become obsolete before the model’s
implementation horizon [9]. This is preferable to assuming
the intervention ceases, as that knowingly introduces bias
by arbitrarily curtailing implementation. Similarly, a
pragmatic approach commonly adopted is that prices are
held constant [24]. The cost year from which prices are
taken or inflated to should be as recent as possible and
clearly stated [25]. Although the assumption that real prices
remain constant is unlikely to hold, relatively small price
changes are unlikely to alter the conclusions of most
analyses. However, abrupt price reductions occurring on
patent expiry of either the intervention of interest or its
comparators might be relevant for reimbursement decisions
[26, 27]. Nevertheless, the consequences of such future
price changes are complex and it is unclear how they
should be best handled in CEA modelling.
3 Simulating Time in Economic Evaluations
An important modelling consideration in CEA is exactly
how the timing of clinical events is simulated. The level of
realism used to simulate the timing of events also
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determines how accurately amounts of time (durations) are
estimated. The main outcomes of CEAs are often defined
in terms of amounts of time, such as the duration of a
disease, quality-adjusted life-years (QALYs) and the
duration (and thus costs) of an intervention. An incorrect
assessment of these durations can therefore lead to inac-
curate cost-effectiveness estimates.
3.1 Modelling Techniques
There are several possible modelling techniques for
CEAs, the choice of which affects the way time is sim-
ulated. These modelling techniques can generally be
divided into (1) decision tree models [28, 29]; (2) Markov
and other state transition models [1, 16, 30]; and (3)
discrete-event simulation models [31]. Decision trees
simulate which clinical events will occur and in what
order, to calculate expected costs and effects. They typi-
cally do not simulate the timing of events (i.e. time is not
modelled explicitly). In state transition models, cohorts of
patients are followed over time as they transition between
a finite number of mutually exclusive possible health
states. Most state transition models are discrete-time
models, in which state membership (i.e. the number of
individuals in a given health state) is only simulated at
the beginning and end of each cycle and so is unknown
between cycles. In discrete-event simulation models the
timing of clinical events is simulated, rather than the
transitions between states over fixed cycles. Therefore,
such models are not restricted to pre-defined paths
between health states. Many discrete-event simulations
are continuous-time models that simulate the exact timing
of each event, but a discrete-time approach is also pos-
sible. Note that the distinctions between modelling tech-
niques are not always clear-cut, e.g. Markov models and
state transition models can also be evaluated using dis-
crete-event simulation.
Recommendations on when to use which modelling
technique have been published previously [32–34]. How-
ever, as a general rule, for interventions with a short
duration and only short-term effects (e.g. painkillers for a
transient migraine), a model that does not explicitly sim-
ulate time, such as a decision tree, may be sufficient.
Decision trees may also suffice for one-off treatments with
long-term effects (e.g. a life-saving appendectomy), pro-
vided that the pay-offs at the end of the decision tree can be
readily appraised and are adjusted to their present value
(see Sect. 4). For interventions with complex long-term
effects (e.g. gastric bypass surgery which may prevent or
delay the onset of diabetes mellitus) or a long duration (e.g.
a cancer screening programme with multiple screening
rounds), it is necessary to use a model that explicitly
models time [1].
3.2 Cycle Lengths and Half-Cycle Corrections
Modelling in discrete time can yield inaccurate cost-ef-
fectiveness estimates. This is because time is inherently
continuous; treating it as discrete within simulation models
leads to an approximation error in the estimation of state
membership, because state membership (and thus treat-
ments and patient characteristics) are then assumed to
remain constant during cycles. Figure 2 shows a continu-
ous survival function, the area under which represents the
total time spent in a state over many individuals. The
discrete approximation of that survival curve is shown by
the step function. The resulting discrete-time approxima-
tion error is given by the lightly-shaded area between the
step function and the continuous survival function. A
continuous-time model best represents reality and is thus
the most accurate approach. A practical reason for discrete-
time modelling is that state membership after each cycle is
easily calculated, whereas continuous-time modelling
requires more advanced modeling techniques, such as
discrete-event simulation.
Discrete-time models generally give sufficient realism
regarding the timing of events, provided that the cycle
length is short enough to ensure that the approximation
error is small. Figures 2a and b show discrete-time
approximations of the same continuous survival function
with long and short cycles, respectively. The figure shows
that the approximation error is larger with the long cycle
length and that the short cycle model better approximates
the continuous-time reality. However, even with a shorter
cycle length the time spent in the state is underestimated.
Furthermore, the solution of using short cycles is not
always practical, as shorter cycles impose larger compu-
tational burdens and very short cycles may be required to
make the approximation error negligible.
To reduce the approximation error without employing
very short cycles, analysts often apply a half-cycle cor-
rection (HCC) or another type of continuity correction in
state transition models [35]. The standard HCC consists of
adding half a cycle of the state membership at the begin-
ning of the first cycle and subtracting half a cycle of the
membership at the end of the last cycle (see Fig. 2) [36].
While a HCC may substantially reduce the approximation
error, the accuracy of the standard HCC has been debated
[37–40], leading to agreement among these authors that the
standard HCC is flawed and the recommendation to use the
cycle-tree HCC (also known as the life table method),
which calculates state membership as the average of state
membership at the beginning and end of each cycle [40].
The cycle-tree HCC is visible in Fig. 2a as the sum of
the lightly and darkly-shaded areas between the discrete-
time step function and the piecewise linear function that
joins state membership at the beginning and the end of each
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cycle. In the case of this convex survival function the HCC
slightly overestimates total state membership, and the
approximation error with a cycle-tree HCC shown by the
darkly shaded area. In this example the standard HCC and
the cycle-tree HCC are equivalent. This is illustrated by
summing the cycle-tree HCCs from each cycle, yielding
the area of the grey column, which represents half a cycle
of state membership at the beginning of the first cycle.
Although an HCC can reduce the discrete-time
approximation error, it cannot fully correct it if the cycle
length is too long. While the remaining approximation
error is small when a short cycle length is used as in
Fig. 2b (it is too small to be visible in the figure), this error
can remain large if the cycle length is long. In Fig 2a for
example, although the HCC reasonably approximates the
survival function in cycles 2 and 3, it overestimates sur-
vival in the first cycle due to the large per-cycle transition
probability. Consequently, the HCC is not sufficient in a
model with a long cycle. Unfortunately, this dependence of
the adequacy of the HCC on the cycle length is not always
reflected in existing guidelines [41]. So, although a cycle-
tree HCC will generally improve accuracy, analysts should
be aware both that the gain in accuracy may be negligible if
the cycle length is already short and that estimates may
remain biased if the cycle length is too long.
When choosing the cycle length, modellers should take
into account the accuracy of the results as well as the
computation time and complexity of the analysis. As
computation time increases with the inverse of the cycle
length, using short cycles may result in impractically long
run times in some models. However, advances in com-
puting power have generally alleviated this concern. Given
this, we recommend not choosing the cycle length simply
based on data availability (e.g. the interval between mea-
surements in a longitudinal study) or using default values
(e.g. 1 year). If the computation time is acceptable, we
recommend using a cycle length that is sufficiently short
that a HCC is not required. Such a cycle length may be
much shorter than is considered clinically relevant, e.g.
chronic diseases that take years to progress may be simu-
lated using a cycle as short as 1 week.
The size of the discrete-time approximation error, and
thus the accuracy of the model results, depend on whether
an HCC is applied and on the size of the transition prob-
abilities in the model, which in turn depends on the cycle
length. An analysis of how the approximation error varies
with these two factors is given in the Appendix, using an
example of a state transition model with two states. To
assess whether a given cycle length is short enough, we
recommend checking the largest probability of leaving the
current state per cycle (i.e. the sum of the transition
probabilities out of the current state). An HCC is likely not
necessary if this probability is lower than 5 % for all states
and time periods, as the relative approximation error must
be smaller than 2.5 % in that case. If this probability
exceeds 40 % for some states, then it is possible that the
results will be inaccurate even with an HCC. In such cases,
we recommend reducing the cycle length or performing a
sensitivity analysis on the cycle length to prove that the
approximation error does not substantially affect the
Fig. 2 The half-cycle correction (HCC) applied in two discrete-time
models approximating a continuous survival function with long
(a) and short (b) cycle lengths. The discrete-time approximation error
is the lightly shaded area between the continuous survival curve and
its discrete approximation represented by the step function. This error
is larger in the model with a longer cycle length (a). The standard
HCC is shown as the sum of the lightly and darkly shaded areas
between the step function and a piecewise linear function joining state
membership at the beginning and end of each cycle. a Shows how the
HCC from each cycle of length t can be gathered, as represented by
the column of shaded triangles, and then summed to yield an area
equivalent to half a cycle of state membership at the start of the first
cycle, represented by the shaded column
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results. In models with a maximum per-cycle probability
between 5 and 40 %, an HCC is probably necessary. An
adequately implemented HCC (we recommend the cycle-
tree HCC) should be sufficient for accurate estimates in
that case.
Note that it is also possible to evaluate a state transition
model as a continuous-time model, so that the approxi-
mation error disappears and no HCC is needed. This is
typically done using discrete-event simulation, but analytic
approaches are sometimes also possible [42].
3.3 Changing the Cycle Length
Calculating the transition probabilities associated with
different cycle lengths in state transition models can be
difficult. For transition probabilities where there is only one
possible transition (and no reverse transitions), the calcu-
lations are relatively straightforward; a transition proba-
bility Pt2 using a cycle of t2 years can be transformed into a
transition probability Pt1 with a cycle of t1 years using
Pt1 ¼ 1 ð1 Pt2Þt1=t2 , and the transition probability Pt1
can be calculated from a transition rate r as Pt1 ¼ 1 ert1
[43, 44]. As the transition probabilities are often estimated
using observational data that do not have the same mea-
surement interval as the cycle length, such conversion
formulas are typically required.
These conversion formulas are not necessarily exact for
transition probabilities in models with multiple states.
Consider the example of a three-state model with an annual
cycle shown in Fig. 3a [45]. Patients progress from
decompensated cirrhosis (DeCirr) to hepatocellular carci-
noma (HeCarc) or death, and patients with HeCarc have an
increased risk of dying. The annual transition probability
from DeCirr to death of 0.14 includes two possible paths:
(1) patients can develop HeCarc and die from HeCarc in
the same year; or (2) patients can die without developing
HeCarc. The univariate conversion of probabilities to a
different cycle length ignores the first possibility, and can
thus lead to incorrect transition probabilities. Figure 3
shows that the annual transition probabilities out of DeCirr
are quite different between the initial values and those
based on conversion to and back from monthly probabili-
ties. Note that this bias cannot be reduced by using an
HCC.
In some cases it is possible to use matrix roots based on
eigendecompositions to change the cycle length in a Mar-
kov model [45]. These matrix roots take into account the
possibility of multiple events per cycle, and thus yield
accurate results. Another solution is to choose a short cycle
length, such that the probability of multiple clinical events
occurring during a cycle is very small, thereby minimising
the bias shown in Fig. 3. Estimating transition probabilities
from observational data for models with short cycles can be
difficult if the observational intervals are long; however,
appropriate statistical methods have been described in the
literature [46].
4 Discounting and Time Preference
People typically prefer to enjoy good things sooner rather
than later. This tendency is called positive time preference
and it means that the present value of future costs or health
effects is less than at the time they will be realised [47].
Discounting is the method used to find the present value of
future outcomes in economic evaluation. Discounting is
generally easy to implement and country-specific CEA
guidelines usually give clear advice on what rates to apply.
The near-universal consensus is to discount costs and
health effects at an equal discount rate that remains con-
stant over time, typically ranging from 3 to 5 % [47].
Nevertheless, discounting remains a much-debated topic
[48], undoubtedly partly because it leads to a worsening of
ICERs for many interventions.
4.1 The Standard Discounting Model
Discounting is usually applied as a discrete function, using
an annual discount factor of dt = (1 ? r)
-(t-1), where r is
the annual discount rate and t is the time period starting at
t = 1 in the discount year. Accordingly, all outcomes
within each given year are discounted equally, irrespective
of when in the year they occur. Although it may be more
theoretically consistent to apply a continuous discount
factor of the form dt = e
-r(t-1), this is rarely applied in
practice.
The literature discussing the rationale for discounting is
extensive [47, 49, 50]. There are two principal arguments
supporting discounting [51]. The first is that positive time
preference is an undeniable aspect of human behaviour and
that social decision makers should reflect private prefer-
ences [50]. The second is that there is an opportunity cost
of spending on health rather than other goods and services:
if money is spent now to achieve future health gains, these
future gains need to be sufficiently large to outweigh the
return on funds allocated to other uses [51]. While there are
competing arguments on what should represent the rate of
return of alternative uses of funds, government borrowing
costs as represented by bond yields are typically used to
represent this intertemporal opportunity cost [48]. Note that
inflation is not a reason to discount and that discounting
should be applied irrespective of any anticipated real price
changes [52].
Most countries recommend discounting costs and effects
at a common rate, in which case the practical advice on
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discounting is straightforward: both costs and effects
should be discounted according to national guidelines and
the analysis should clearly state the rates applied. In the
interests of comparability between countries, it is useful to
supplement the base case with estimates for the rates of 3
and 5 %, as recommended by The Panel on Cost-Effec-
tiveness in Health and Medicine [48]. These rates are also a
reasonable recommendation for countries without official
discounting guidance.
A univariate sensitivity analysis featuring discount
rates ranging from 0 to 6 % is a common requirement of
CEA guidelines. When conducting such sensitivity anal-
yses, the discount rates on costs and effects should be
varied together, so that equal discounting is maintained.
Such sensitivity analyses usefully illustrate the effects of
discounting to decision makers and should be reported.
Nevertheless, analysts should not overemphasise undis-
counted outcomes, as this may give the impression that
the intervention is more cost effective than in reality.
What is often not appreciated is that the relative ranking
of interventions in terms of ICERs may be less sensitive
to discounting than the ICER itself. Discount rates should
not be varied during probabilistic sensitivity analysis as
the appropriate discount rate is not usually subject to
parameter uncertainty.
Discounting is used to estimate the present value of
future costs and effects at a single point in time known as
the discount year. Although the choice of discount year
will affect the absolute size of discounted costs and effects,
it does not influence ICERs under equal discounting, as
adjusting the discount year results in equiproportionate
changes in the numerator and the denominator of the ICER.
Accordingly, the choice of discount year is usually not
critical to the outcome of a CEA [53], but may be relevant
to cost analyses. Nevertheless, it is conventional practice to
use the year the intervention begins as the discount year, as
this represents a decision year in which the intervention
may or may not be implemented. However, it is necessary
to maintain a common discount year when comparing
multiple possible initiation years, for example with alter-
native start ages for prophylactic statin therapy in a given
cohort.
The adequacy of the standard discounting model with
constant, equal discount rates for costs and effects has been
debated, as there is considerable evidence that individuals’
time preferences do not accord with this model [54]. For
instance, individuals tend to demonstrate decreasing rates
of time preference as outcomes become more distant [55].
This has prompted proposals of non-constant discounting
in which the discount rate falls over time [49, 56]. How-
ever, such discounting results in dynamic inconsistency,
whereby the optimal policy choice can alter as time
advances and outcomes become more immediate [48].
Apparently, the only national CEA guidelines recom-
mending a declining discount rate are those of France,
which permit a fall in the discount rate after 30 years [57],
although the guidance is ambiguous regarding implemen-
tation. A declining discount rate has also been recom-
mended by the UK Treasury [55], but this guidance is not
CEA specific.
4.2 Differential Discounting
Differential discounting is one deviation from standard
discounting that has been adopted in several CEA guide-
lines. It is the application of a different (typically lower)
discount rate to health effects than to costs [58]. The pri-
mary justification for differential discounting is the
expectation of growth in the willingness to pay for health
over time, represented either by the value of health or the
cost-effectiveness threshold [58, 59]. The CEA guidelines
of Belgium, The Netherlands and Poland require
Fig. 3 The effect of ignoring the possibility of multiple events per
cycle when changing the cycle length in state transition models.
A Markov model with three health states is shown: decompensated
cirrhosis (DeCirr), hepatocellular carcinoma (HeCarc) and death.
a Shows the model with annual cycle; b shows the model transformed
to monthly cycles using a univariate conversion of probabilities; and
c shows the implied annual transition probabilities of the Markov
model using monthly cycles (adapted from Chhatwal et al. [45])
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differential discounting, as did the UK’s prior to 2004 [53,
60]. Differential discounting improves the ICERs of many
interventions, especially those with a long lag between
costs and benefits, such as preventive interventions.
Differential discounting can complicate the interpreta-
tion of cost-effectiveness evidence, presenting problems
that have yet to be documented or resolved. One long-
recognised issue is the so-called postponing paradox,
whereby an intervention’s ICER declines if implementa-
tion is postponed to a cohort in the following year, sup-
posedly leading decision makers to eternally postpone
implementation [61]. The paradox has been dismissed as
irrelevant, because CEA informs what interventions to
implement in a given period rather than when to allocate
resources [62]. Despite this, there remain two closely
related problems.
The first is that the choice of discount year can influence
ICERs. Setting the discount year to a period before treat-
ment initiation will reduce the ICER relative to the more
common practice of discounting to the year of treatment
initiation. For example, a Dutch CEA of cervical screening
strategies starting at age 30 years in women who received
HPV vaccination discounted the costs and effects of
screening to the age of vaccination at 12 years [63]. Under
the Dutch discount rates of 4 % for costs and 1.5 % for
effects, the 18 additional years of discounting resulted in
ICERs that were approximately 35 % lower than would
have been the case had outcomes been discounted to the
initiation of screening. This should be avoided by setting
the discount year to the year of treatment initiation. In the
case of comparisons of multiple possible intervention ages
for a given cohort, the discount year should be held as the
earliest intervention year.
The second problem related to the postponing paradox is
that ICERs fall with the addition of future cohorts to a
model [53]. As mentioned above, the simulation of indirect
effects of vaccination requires the inclusion of multiple
future cohorts, which will improve the ICER under dif-
ferential discounting, all else being equal. Indeed, this
effect can become so pronounced when the number of
future cohorts is large that ICERs under differential dis-
counting can become even lower than ICERs without dis-
counting. For example, a CEA of HPV vaccination that
employed 100 years of incident cohorts found an ICER of
£2385/QALY under differential discounting rates of 6 and
1.5 % for costs and effects, respectively, whereas the
undiscounted ICER was £4320/QALY [64]. So, although
discounting typically inflates ICERs when beneficial
effects occur after costs are incurred, this can be out-
weighed by the implicit increase in the value of health
effects implied by differential discounting if the analysis
extends sufficiently far into the future. This effect of dif-
ferential discounting compromises the comparability of
estimates between CEAs with different numbers of future
cohorts.
We make three recommendations for those countries
requiring differential discounting. The first is to also report
outcomes for equal discounting at both 3 and 5 %. Second,
clearly define the simulated cohorts, including their ages at
the date the intervention begins. Third, always report the
discount year and intervention start year for all strategies
modelled.
5 Discussion
The methodological issues regarding time have important
implications for evaluating the cost effectiveness of
healthcare strategies. This applies to each of the three
principal issues considered in this article: (1) the choice of
which cohorts to simulate in a model and for how long; (2)
how to simulate time in a CEA model; and (3) how to
discount future costs and effects. Aspects of these ques-
tions can be complex and abstract (e.g. the postponing
paradox); nevertheless, these are important elements of the
correspondence between models and the real-life policy
choices they inform. Therefore, applied CEA modellers
should have an appreciation of the issues regarding time
and reflect them appropriately in the simulations they
conduct to help inform policy makers.
Single-cohort models are often sufficient to simulate an
intervention’s cost effectiveness and are widely used.
However, some situations require the simulation of multi-
ple cohorts, which then raises questions of how the
implementation period and analytic time horizon should be
extended to accommodate future cohorts and whether to
report disaggregated subgroup-specific estimates. This
article’s key recommendations are summarised in Table 1.
The choice of cohorts simulated should be made explicit,
as should the decision to report aggregated results or
otherwise. Implementation periods and analytic time hori-
zons should be sufficiently long to avoid curtailing the
simulation of interventions and the assessment of their
outcomes. One exception to this recommendation is the
multi-cohort modelling of interventions with shared
effects, in which the imposition of finite time horizons that
censor the assessment of effects for at least some cohorts
seems largely inevitable. Further research is required into
the most appropriate approach in this case.
The issue of how to simulate the timing of events using
different modelling techniques has received much atten-
tion in the literature. Although the limitations of models
not explicitly simulating time have previously been
recognised, decision trees are still used. As long as
models do simulate time explicitly and cycle lengths are
set appropriately within discrete time models, the choice
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between discrete-time and continuous-time modelling is
not necessarily critical. The cycle length determines how
well discrete-time models approximate continuous-time
processes and thus is an important modelling choice.
Although HCCs can reduce some of the inaccuracies
associated with long cycle lengths, we generally recom-
mend making the cycle length sufficiently short to ensure
the differences between continuous-time and discrete-time
models are negligible, provided that a short cycle is
computationally feasible. Finally, adjusting transition
probabilities for different cycle lengths is an underappre-
ciated issue and analysts should always take care when
making such conversions.
Discounting remains a much-debated topic in CEA,
probably partly due to the deterioration of ICERs after
discounting in many cases. Discounting is not always
intuitive, especially to non-economists, and it is under-
standably disconcerting that ICERs can vary profoundly
with small changes in the discount rate, especially when
the rationale for one rate over another appears weak. The
particular rates and form of discounting applied should
have a sound normative basis and not be driven by a desire
to find some interventions cost effective. Alternatives to
constant-rate discounting (e.g. hyperbolic discounting) do
not accord with standard economic theory and may
potentially lead to logical inconsistencies and unanticipated
consequences. Accordingly, we strongly recommend
applying the discount rates stipulated in the relevant CEA
guidance.
Differential discounting is one departure from standard
discounting that has achieved sufficient support among
health economists to be adopted in some national CEA
guidelines. However, questions remain whether the dif-
ferentials between rates currently employed are empirically
justified given plausible rates of threshold growth [65].
Similarly, it is unclear how differential discounting should
be applied in multi-cohort models. This is especially rele-
vant for infectious disease models that extend far into the
future, as the implied growth in the willingness to pay for
health over a long period can be substantial.
A common thread linking the three topics considered in
this article is the correspondence of models to the policy
questions they guide. Recognising that models need to
closely correspond to policy questions if they are to pro-
vide reliable guidance prompts two further important
considerations. First, judging how well a given model
corresponds to a particular policy question requires a clear
model description. Unfortunately, many aspects of time are
often not explicitly noted or are incompletely described,
including the implementation period, simulation cycle
length and discount year. Therefore, it can be unclear what
analytic approach has been adopted and why. Although
technical details regarding model implementation that do
not affect results can sometimes be omitted in the
description of applied CEAs, many issues regarding time
can have a strong impact on the estimated cost effective-
ness and should thus be reported.
Second, it is important that policy questions are framed
in a way that is meaningful to CEA. For example, a deci-
sion maker may quite naturally ask what the cost effec-
tiveness of a given intervention in the population over the
next 5 years is. Such a question may not be meaningfully
applicable to many long-duration interventions such as
screening programmes. Accordingly, dialogue between
Table 1 Key recommendations
Topic area Key recommendations
Cohort selection and model
structure
Clearly describe the scope of the policy choice regarding who will receive in the intervention and for how long
Clearly define the simulated recipient cohorts, their birth years, intervention start dates and the time horizon of
the model
Use a multi-cohort model if there are substantial differences in cost effectiveness between cohorts or if the
intervention has shared effects; otherwise, use a single-cohort model
Set an implementation period that does not constrain cohorts from completing the intervention if possible
Justify the choice of aggregate or disaggregate reporting when using multi-cohort models
Simulating time Use short cycle lengths when modelling in discrete time or use a continuous-time model
When using state transition models, assess whether a cycle-tree half-cycle correction is necessary
Take care when converting rates and probabilities where multiple transitions are possible
Discounting Follow national CEA guidelines and clearly state which rates were applied
Report outcomes for discount rates of 3 and 5 % in the interests of comparability
Clearly state the discount year
When using differential discounting in multi-cohort models, acknowledge the fact that ICERs can be inflated by
the inclusion of future cohorts
CEA cost-effectiveness analysis, ICER incremental cost-effectiveness ratio
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modellers and decision makers is essential, not only to
ensure that models correspond with policy questions but
also that the right policy questions are posed in the first
place.
A limitation of this article is that it naturally cannot
address all relevant issues regarding time in CEA mod-
elling. It has not considered extrapolation of trial data and
the influence of alternative survival functions on cost-ef-
fectiveness estimates, which have been addressed else-
where [66, 67]. Similarly, it has not reviewed recent work
on the graphical presentation of net benefit and its uncer-
tainty over time [68, 69], or how time affects value of
information analysis and the possibility of delaying
implementation for further research [70, 71]. We have
investigated the effects of the cycle length and the HCC on
the discrete-time approximation error, leading to suggested
bounds on the appropriate size of the per-cycle transition
probabilities. Further research is necessary to provide a full
exposition of these results. More generally, our recom-
mendations are based on the literature and the authors’
CEA modelling experience rather than being substantiated
with examples.
6 Conclusions
Choices around time in health economic evaluations can be
influential, but unfortunately they can also be conceptually
challenging for both analysts and policy makers. We make
a number of specific recommendations, but the most
important is the general suggestion that analysts think
carefully about how considerations of time may impact on
results and that they explicitly state and justify their
modelling choices.
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Appendix: Effects of Cycle Length and Half-Cycle
Correction on Discrete-Time Approximation
Error
Consider a simple two-state state transition model in which
the only possible transition is from alive to dead. The
model can be analysed using either discrete or continuous
time. Let t denote the time in the model, with the unit of
measurement equal to the cycle length in a discrete-time
analysis, so that t = 1 corresponds to the end of the first
cycle. The proportion of a cohort alive at any point
between the cycles can be calculated under the assumption
of constant hazard and using the per-cycle transition
probability, p. For a cohort alive at t = 0, the proportion
alive at time t is given by f(t) = elog(1-p)t, where t is
constrained to integer values for the discrete-time model,
so that the proportion alive at time t = 1 is f(1) = 1 - p.
When evaluated in continuous time, the amount of time
spent in the alive state during the first cycle can be cal-
culated by integrating f(t), which yields that
Texact ¼
R 1
0
elogð1pÞtdt ¼ p
logð1pÞ. When evaluated in dis-
crete time without HCC, the time spent in this state over
the first cycle is TNoHCC = 1 - p, i.e. the state membership
at the end of the cycle; with a cycle-tree HCC, this is
THCC = 1 - 0.5p, which is the average state membership
at the beginning and the end of the cycle. The state
membership as a function of time is illustrated in Fig. 4, for
Fig. 4 State membership as a function of time in a continuous-time
two-state model with states alive and dead, as well as the implied
half-cycle correction approximations to the state membership func-
tion. HCC half-cycle correction
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both the continuous-time model and the discrete-time
model with HCC.
The discrete-time approximation error can be defined as
the relative difference in the time spent between the con-
tinuous-time approach and the discrete-time approach,
which is given by TNoHCCTExact
TExact
¼ p1
p
log 1 pð Þ  1 and
THCCTExact
TExact
¼ 0:5p1
p
log 1 pð Þ  1, without HCC and with
HCC, respectively. The absolute values of these functions
are shown in Fig. 5, as the approximation errors with and
without HCC have a different sign in this case due to the
convexity of the survival function.
In models with more than two states, for each state there
is not only a bias associated with patients leaving the state
before the end of a cycle, but also a bias due to patients
entering the state during the cycle. These two biases have
opposite directions, and so will offset each other to a
degree. Consequently, the total approximation error cannot
be larger than the maximum of these two biases. The size
of the bias associated with patients leaving the state before
the end of a cycle can be described by the functions in
Fig. 5, with these functions applied to the probability that a
patient leaves a state during a cycle, i.e. the sum of all
transition probabilities out of this state.
The bias associated with patients entering a state during
a cycle has the same size in absolute terms (i.e. THCC -
TExact or TNoHCC - TExact) as the bias associated with the
probability of leaving the state during a cycle for the state
from which the patients are coming. This fact is illustrated
in Fig. 4, where the area between the exact state mem-
bership curve and the HCC approximation is identical for
both the dead state and the alive state: the overestimation in
the time spent in the alive state (with HCC) equals the
underestimation of the time spent in the dead state.
Although the approximation error relative to the time spent
in the initial state (i.e. alive) remains constant over cycles,
the approximation error relative to the time spent in the
absorbing state (i.e. dead) is initially high and decreases
over cycles. Note, therefore, that the relative error for the
absorbing state will be larger than shown in Fig. 5 in early
cycles. These large approximation errors typically only
occur in the first cycles of the model, when there can be
large relative increases in the state membership during a
cycle for states with initial state membership equal to 0.
When summed over a number of cycles of the model, the
total relative bias due to patients entering a state during a
cycle will thus be attenuated. Numerical experimentation
with state transition models with more than two states
suggests that the approximation error in any state in a state
transition model is rarely larger than the relative bias given
in Fig. 5, unless the model is run for a small number (e.g.
less than 50) of cycles.
The benefits of the HCC can be shown in the illustrative
example of a two-state model. An illustrative maximum
bias of 2.5 % is achieved when the probability of leaving
the current state does not exceed 0.05 in a model without
HCC or 0.40 in a model with HCC. Thus, a tolerable level
of approximation error can be achieved at much higher
transition probabilities if a HCC is applied. We did not
study the effect of the approximation error on comparative
cost-effectiveness outcomes such as ICERs, and we also
ignored the effects of discounting in our analysis. However,
the biases due to the discrete-time approximation in the
costs and health effects under different treatments should
all have the same direction, so that the bias in cost-effec-
tiveness ratios may be much smaller than the bias in the
time spent in a state.
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